Integer (ITGR) Q4 2024 earnings summary

Executive summary

• Achieved strong Q4 2024 sales growth of 11% year-over-year to $449M, with full-year sales up 10% to $1.717B and Adjusted Operating Income up 20% over 2023, outpacing sales growth twofold.

• Completed the divestiture of Electrochem, focusing the company as a pure-play medical device firm, and executed two strategic acquisitions: Precision Coating ($152M) and VSI Parylene ($28M), both expected to be accretive and expand proprietary coating capabilities.

• Maintained leverage at 2.6x Adjusted EBITDA at year-end 2024, at the low end of the target range, supporting ongoing tuck-in acquisitions.

• Strategy focuses on sustained above-market growth, vertical integration, and expanding presence in high-growth medical device markets, with a pipeline to maintain sales growth 200bps above market.

Financial highlights

• Q4 2024 sales reached $449M, up 11% year-over-year; full-year 2024 sales were $1.717B (+10%), with Adjusted EBITDA of $361M (+19%) and Adjusted Operating Income of $285M (+20%).

• Adjusted Net Income for 2024 was $184M, with Adjusted EPS of $5.30 (+15%).

• Free cash flow for 2024 was $100M (+65%), with $205M in cash flow from operations.

• Adjusted EBITDA for Q4 was $95M (+11%), and Adjusted Operating Income grew 13% to $76M.

• GAAP income from continuing operations for 2024 was $121M (+36%), with GAAP diluted EPS of $3.40 (+29%).

Outlook and guidance

• 2025 sales expected between $1.846B and $1.880B, up 8%-10% year-over-year, with organic sales growth projected at 6%-8%.

• Adjusted EBITDA forecasted at $401M-$422M (+11%-17%), Adjusted Operating Income at $315M-$331M (+11%-16%), and Adjusted EPS of $5.84-$6.20 (+10%-17%).

• Adjusted Net Income expected at $208M-$221M (+13%-20%).

• Free cash flow for 2025 projected at $110M-$130M; cash flow from operating activities expected at $225M-$245M.

• Year-end net total debt expected at $1.03B-$1.05B, with leverage ratio within 2.5-3.5x EBITDA.